{"id":73214,"date":"2026-04-17T13:27:06","date_gmt":"2026-04-17T07:57:06","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=73214"},"modified":"2026-04-17T13:27:07","modified_gmt":"2026-04-17T07:57:07","slug":"nectar-lifesciences-q4-results-2026-preview","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/","title":{"rendered":"Nectar Lifesciences Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook"},"content":{"rendered":"<p>Nectar Lifesciences (NSE: NECTARLIFE) is preparing to announce its Q4 FY26 financial results for the quarter ending March 31, 2026. With the stock trading at Rs 72 and a 52-week range of Rs 60\u2013Rs 115, the Q4 FY26 results will be a pivotal event for investors tracking the Pharma sector. This article covers the confirmed results date, Q4 FY26 analyst earnings estimates, five key performance drivers, five risks to monitor, and analyst ratings with price targets ahead of the results announcement.<\/p><p>Q4 FY26 (January to March 2026) is the final quarter of the financial year, carrying special importance as it determines the full-year FY26 performance baseline, sets FY27 estimate benchmarks, and typically triggers final dividend announcements. For Pharma companies, Q4 is historically a seasonally important quarter influenced by year-end government spending, monsoon positioning, and management guidance for the year ahead.<\/p><p>Investors should monitor three data points when results are announced: the revenue and PAT numbers relative to the estimates provided in this article, any formal FY27 guidance, and the dividend recommendation from the board. All three will influence the stock&#8217;s near-term trajectory. For real-time analysis and SEBI-registered expert views on Nectar Lifesciences, visit&nbsp;<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Nectar_Lifesciences_Q4_Results_2026_Date\" title=\"Nectar Lifesciences Q4 Results 2026 Date\">Nectar Lifesciences Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Why_This_Quarter_Matters\" title=\"Why This Quarter Matters\">Why This Quarter Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Nectar_Lifesciences_Q4_FY26_Earnings_Estimates\" title=\"Nectar Lifesciences Q4 FY26 Earnings Estimates\">Nectar Lifesciences Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#5_Key_Factors_That_Will_Drive_Nectar_Lifesciences_Q4_FY26_Performance\" title=\"5 Key Factors That Will Drive Nectar Lifesciences Q4 FY26 Performance\">5 Key Factors That Will Drive Nectar Lifesciences Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#API_Export_Revenue_Growth\" title=\"API Export Revenue Growth\">API Export Revenue Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#US_FDA_Compliance_Progress\" title=\"US FDA Compliance Progress\">US FDA Compliance Progress<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Formulations_Segment_Expansion\" title=\"Formulations Segment Expansion\">Formulations Segment Expansion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Debt_Reduction_Trajectory\" title=\"Debt Reduction Trajectory\">Debt Reduction Trajectory<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Antibiotic_API_Market_Share\" title=\"Antibiotic API Market Share\">Antibiotic API Market Share<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#5_Risks_to_Watch_in_Nectar_Lifesciences_Q4_FY26\" title=\"5 Risks to Watch in Nectar Lifesciences Q4 FY26\">5 Risks to Watch in Nectar Lifesciences Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#USFDA_Warning_Letter_Risk\" title=\"USFDA Warning Letter Risk\">USFDA Warning Letter Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Debt_Servicing_Pressure\" title=\"Debt Servicing Pressure\">Debt Servicing Pressure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#API_Price_Erosion\" title=\"API Price Erosion\">API Price Erosion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Currency_Volatility\" title=\"Currency Volatility\">Currency Volatility<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Regulatory_Risk_in_Export_Markets\" title=\"Regulatory Risk in Export Markets\">Regulatory Risk in Export Markets<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Nectar_Lifesciences_Share_Price_and_Analyst_Ratings\" title=\"Nectar Lifesciences Share Price and Analyst Ratings\">Nectar Lifesciences Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#What_is_the_Nectar_Lifesciences_Q4_results_2026_date\" title=\"What is the Nectar Lifesciences Q4 results 2026 date?\">What is the Nectar Lifesciences Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#What_is_the_Nectar_Lifesciences_Q4_FY26_PAT_estimate\" title=\"What is the Nectar Lifesciences Q4 FY26 PAT estimate?\">What is the Nectar Lifesciences Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#What_is_Nectar_Lifesciencess_share_price_ahead_of_Q4_results\" title=\"What is Nectar Lifesciences&#8217;s share price ahead of Q4 results?\">What is Nectar Lifesciences&#8217;s share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Will_Nectar_Lifesciences_declare_a_dividend_in_Q4_2026\" title=\"Will Nectar Lifesciences declare a dividend in Q4 2026?\">Will Nectar Lifesciences declare a dividend in Q4 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Which_analysts_have_a_Buy_rating_on_Nectar_Lifesciences\" title=\"Which analysts have a Buy rating on Nectar Lifesciences?\">Which analysts have a Buy rating on Nectar Lifesciences?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#What_were_Nectar_Lifesciences_Q3_FY26_results\" title=\"What were Nectar Lifesciences Q3 FY26 results?\">What were Nectar Lifesciences Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#When_do_Infosys_and_TCS_announce_Q4_results_2026\" title=\"When do Infosys and TCS announce Q4 results 2026?\">When do Infosys and TCS announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Is_Nectar_Lifesciences_a_good_investment_ahead_of_Q4_results\" title=\"Is Nectar Lifesciences a good investment ahead of Q4 results?\">Is Nectar Lifesciences a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q4-results-2026-preview\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Nectar_Lifesciences_Q4_Results_2026_Date\"><\/span><strong>Nectar Lifesciences Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Get free investment predictions and live Q4 result alerts on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><p>Nectar Lifesciences has scheduled its Q4 FY26 results for May 2026 (Expected). The board of directors will convene to approve the audited consolidated financial statements for the quarter and full year ended March 31, 2026, and to consider a final dividend recommendation. The trading window for designated employees is closed until 48 hours after the results announcement, as per SEBI regulations.<\/p><p>For context on the broader Q4 FY26 results season across the IT and other high-visibility sectors, refer to the earnings calendar below.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Q4 FY26 Results Date<\/strong><\/td><td><strong>Article Link<\/strong><\/td><\/tr><tr><td>TCS<\/td><td>April 9, 2026<\/td><td><a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">Read TCS Q4 Preview<\/a><\/td><\/tr><tr><td>Infosys<\/td><td>April 23, 2026<\/td><td><a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Read Infosys Q4 Preview<\/a><\/td><\/tr><tr><td>Nectar Lifesciences<\/td><td>May 2026 (Expected)<\/td><td>This article<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_Quarter_Matters\"><\/span><strong>Why This Quarter Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Q4 FY26 is the final quarter of the financial year \u2014 it determines full-year FY26 performance, establishes FY27 estimate baselines, and triggers final dividend announcements. For Nectar Lifesciences specifically, Q4 FY26 matters because the stock has delivered a -28% return over the past year, making the quarter&#8217;s growth trajectory and management guidance crucial for sentiment recovery.<\/p><p>Institutional investors typically rebalance portfolios at the end of March, and Q4 results provide the data clarity needed to assess whether to increase or reduce positions ahead of the new financial year. Analyst price targets \u2014 ranging from Rs 80 to Rs 85 \u2014 will be updated post-results based on the actual Q4 FY26 performance and FY27 guidance.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Nectar_Lifesciences_Q4_FY26_Earnings_Estimates\"><\/span><strong>Nectar Lifesciences Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132431\/nectar-lifesciences_estimates-1024x536.jpg\" alt=\"Nectar Lifesciences Q4 FY26 Earnings Estimates\" class=\"wp-image-73222\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132431\/nectar-lifesciences_estimates-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132431\/nectar-lifesciences_estimates-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132431\/nectar-lifesciences_estimates-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132431\/nectar-lifesciences_estimates-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132431\/nectar-lifesciences_estimates-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132431\/nectar-lifesciences_estimates-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132431\/nectar-lifesciences_estimates.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Access premium SEBI-registered research on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><p>Analysts from brokerages including MOFSL, YES Securities, JM Financial, and ICICI Direct have published Q4 FY26 preview estimates for Nectar Lifesciences. Consensus revenue estimate stands at Rs 680\u2013730 Cr, compared to Rs 640 Cr in Q3 FY26. PAT is estimated at Rs 35\u201350 Cr, with margin projections of EBITDA 13\u201315%. These estimates are based on publicly available information and may differ from actual results.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><td><strong>Key Driver<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 640 Cr<\/td><td>Rs 680\u2013730 Cr<\/td><td>Seasonal demand + YoY growth<\/td><\/tr><tr><td>PAT<\/td><td>Rs 30 Cr<\/td><td>Rs 35\u201350 Cr<\/td><td>Operating leverage improvement<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 12.8%<\/td><td>EBITDA 13\u201315%<\/td><td>Cost control + pricing<\/td><\/tr><tr><td>Growth (YoY)<\/td><td>\u2014<\/td><td>8\u201314% YoY<\/td><td>Volume\/price mix<\/td><\/tr><tr><td>Dividend (Expected)<\/td><td>\u2014<\/td><td>Rs 1\u20131.5 per share<\/td><td>Board discretion<\/td><\/tr><\/tbody><\/table><\/figure><p>Beyond the headline numbers, investors should watch management commentary on two additional points: the FY27 revenue and margin guidance, and the dividend declaration. The FY27 outlook will carry more weight for the stock&#8217;s re-rating than the Q4 numbers themselves in the current market environment.<\/p><p>Screen Nectar Lifesciences fundamentals, historical financials, and peer comparisons on the <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_That_Will_Drive_Nectar_Lifesciences_Q4_FY26_Performance\"><\/span><strong>5 Key Factors That Will Drive Nectar Lifesciences Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"API_Export_Revenue_Growth\"><\/span><strong>API Export Revenue Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nectar Lifesciences&#8217; core business \u2014 active pharmaceutical ingredient (API) manufacturing \u2014 benefits from rising global generic drug demand and China+1 sourcing shifts. Q4 FY26 export revenues are expected to show 8\u201314% growth.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"US_FDA_Compliance_Progress\"><\/span><strong>US FDA Compliance Progress<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nectar&#8217;s manufacturing facilities have been working through remediation processes following previous observations. Successful clearance of pending USFDA items would unlock US market potential and improve the quality of revenue mix.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Formulations_Segment_Expansion\"><\/span><strong>Formulations Segment Expansion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The company has been growing its formulations segment alongside APIs. Higher-margin formulation revenues reduce dependence on commodity API cycles and improve overall profitability.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Debt_Reduction_Trajectory\"><\/span><strong>Debt Reduction Trajectory<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nectar Lifesciences has been managing elevated debt levels. Q4 collections from export customers and domestic formulation sales can help bring down net debt, which is a critical catalyst for re-rating.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Antibiotic_API_Market_Share\"><\/span><strong>Antibiotic API Market Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nectar is a significant player in antibiotic APIs \u2014 a segment benefiting from post-COVID healthcare investment and rising branded generic demand in emerging markets. Market share gains here drive volume growth.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Nectar_Lifesciences_Q4_FY26\"><\/span><strong>5 Risks to Watch in Nectar Lifesciences Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"USFDA_Warning_Letter_Risk\"><\/span><strong>USFDA Warning Letter Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Any fresh FDA observation or warning letter on manufacturing facilities could restrict US market access and materially affect revenue and sentiment.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Debt_Servicing_Pressure\"><\/span><strong>Debt Servicing Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>High debt levels maintain interest cost pressure that can significantly affect PAT even when EBITDA grows in line with estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"API_Price_Erosion\"><\/span><strong>API Price Erosion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Commodity API prices are subject to global supply-demand dynamics, including competition from Chinese manufacturers. Pricing pressure can offset volume growth benefits.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Currency_Volatility\"><\/span><strong>Currency Volatility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nectar derives a significant portion of revenues from exports. Rupee appreciation against key currencies can reduce realisation on export invoices.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Regulatory_Risk_in_Export_Markets\"><\/span><strong>Regulatory Risk in Export Markets<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Varying pharmacopoeia standards and regulatory approvals across export markets add compliance complexity. Delays in new country approvals can slow revenue ramp.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Nectar_Lifesciences_Share_Price_and_Analyst_Ratings\"><\/span><strong>Nectar Lifesciences Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132523\/nectar-lifesciences-share_analyst-1024x536.jpg\" alt=\"Nectar Lifesciences Share Price and Analyst Ratings\" class=\"wp-image-73223\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132523\/nectar-lifesciences-share_analyst-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132523\/nectar-lifesciences-share_analyst-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132523\/nectar-lifesciences-share_analyst-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132523\/nectar-lifesciences-share_analyst-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132523\/nectar-lifesciences-share_analyst-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132523\/nectar-lifesciences-share_analyst-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132523\/nectar-lifesciences-share_analyst.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Nectar Lifesciences is trading at Rs 72 as of early April 2026, against a 52-week high of Rs 115 and 52-week low of Rs 60. The 1-year return of -28% reflects the broader sector headwinds and company-specific factors discussed in this article. Market capitalisation stands at Rs 1,000 Cr. The -28% return has compressed valuations, creating a potential entry point for investors who believe the FY27 recovery story is intact.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Investment Thesis<\/strong><\/td><\/tr><tr><td>MOFSL<\/td><td>Neutral<\/td><td>Rs 85<\/td><td>API exports drive revenue<\/td><\/tr><tr><td>YES Securities<\/td><td>Neutral<\/td><td>Rs 82<\/td><td>Debt reduction key watchpoint<\/td><\/tr><tr><td>JM Financial<\/td><td>Hold<\/td><td>Rs 78<\/td><td>US FDA compliance improving<\/td><\/tr><tr><td>ICICI Direct<\/td><td>Neutral<\/td><td>Rs 80<\/td><td>Formulation revenues growing<\/td><\/tr><\/tbody><\/table><\/figure><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Nectar Lifesciences&#8217;s live price, receive SEBI-backed research alerts, and access pre- and post-results analysis from registered analysts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Nectar Lifesciences is at an inflection point in Q4 FY26 \u2014 improving API volumes, US FDA compliance progress, and debt reduction are the three factors that will determine post-results sentiment. Revenue of Rs 680\u2013730 Cr and PAT improvement to Rs 35\u201350 Cr from Q3&#8217;s Rs 30 Cr would mark a sequential recovery. Analyst consensus is Neutral, with meaningful upside contingent on FDA compliance milestones.<\/p><p>This article is for informational and educational purposes only. Investors are advised to consult a SEBI-registered financial advisor before making investment decisions. Historical performance and analyst estimates are not guarantees of future results.<\/p><p>For more Q4 FY26 results previews across sectors, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Nectar_Lifesciences_Q4_results_2026_date\"><\/span><strong>What is the Nectar Lifesciences Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Nectar Lifesciences Q4 FY26 results date is May 2026 (Expected). The board of directors will meet to approve audited financial statements for the quarter ended March 31, 2026, and consider a final dividend recommendation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Nectar_Lifesciences_Q4_FY26_PAT_estimate\"><\/span><strong>What is the Nectar Lifesciences Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts estimate Nectar Lifesciences Q4 FY26 PAT at Rs 35\u201350 Cr, based on revenue of Rs 680\u2013730 Cr and margin of EBITDA 13\u201315%. Actual results may differ from consensus estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Nectar_Lifesciencess_share_price_ahead_of_Q4_results\"><\/span><strong>What is Nectar Lifesciences&#8217;s share price ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nectar Lifesciences is trading at Rs 72 as of early April 2026. The 52-week high is Rs 115 and the low is Rs 60. The 1-year return is -28% and market cap is Rs 1,000 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_Nectar_Lifesciences_declare_a_dividend_in_Q4_2026\"><\/span><strong>Will Nectar Lifesciences declare a dividend in Q4 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nectar Lifesciences is expected to consider Rs 1\u20131.5 per share as a final dividend at the Q4 FY26 board meeting. The actual dividend will be declared by the board and is subject to the company&#8217;s profitability and capital allocation policy.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Which_analysts_have_a_Buy_rating_on_Nectar_Lifesciences\"><\/span><strong>Which analysts have a Buy rating on Nectar Lifesciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>&nbsp;have a positive rating on Nectar Lifesciences heading into Q4 FY26 results.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_were_Nectar_Lifesciences_Q3_FY26_results\"><\/span><strong>What were Nectar Lifesciences Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Nectar Lifesciences reported revenue of Rs 640 Cr and PAT of Rs 30 Cr in Q3 FY26 (October\u2013December 2025), with margin at EBITDA 12.8%. These form the sequential base against which Q4 FY26 results will be measured.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_do_Infosys_and_TCS_announce_Q4_results_2026\"><\/span><strong>When do Infosys and TCS announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS announced Q4 FY26 results on April 9, 2026. Read the full <a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">TCS Q4 Results 2026 preview<\/a>. Infosys announced Q4 FY26 results on April 23, 2026. Read the full <a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Infosys Q4 Results 2026 preview<\/a>.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Nectar_Lifesciences_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Is Nectar Lifesciences a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This depends on your risk appetite, investment horizon, and portfolio context. Nectar Lifesciences has compelling factors including api export revenue growth and us fda compliance progress, but also faces risks including usfda warning letter risk. Consult a SEBI-registered financial advisor before making investment decisions. Use the&nbsp; to assess fundamentals independently.<\/p><p>Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE\/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/motisons-jewellers-q4-results-2026\">Motisons Jewellers Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/motilal-oswal-financial-services-q4-results-2026\">Motilal Oswal Financial Services Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/moschip-technologies-q4-results-2026\">Moschip Technologies Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/morepen-laboratories-q4-results-2026\">Morepen Laboratories Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/morarjee-textiles-q4-results-2026\">Morarjee Textiles Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Nectar Lifesciences (NSE: NECTARLIFE) is preparing to announce its Q4 FY26 financial results for the quarter ending March 31, 2026. With the stock trading at Rs 72 and a 52-week range of Rs 60\u2013Rs 115, the Q4 FY26 results will be a pivotal event for investors tracking the Pharma sector. This article covers the confirmed<\/p>\n","protected":false},"author":26,"featured_media":73219,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-73214","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"_edit_lock":["1776412700:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:8:{s:81:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/nectar-lifesciences_estimates.jpg\";a:2:{s:2:\"id\";i:73222;s:11:\"source_type\";s:13:\"media-library\";}s:90:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/nectar-lifesciences_estimates-1024x536.jpg\";a:2:{s:2:\"id\";i:73222;s:11:\"source_type\";s:13:\"media-library\";}s:113:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132431\/nectar-lifesciences_estimates.jpg\";a:2:{s:2:\"id\";i:73222;s:11:\"source_type\";s:13:\"media-library\";}s:122:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132431\/nectar-lifesciences_estimates-1024x536.jpg\";a:2:{s:2:\"id\";i:73222;s:11:\"source_type\";s:13:\"media-library\";}s:85:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/nectar-lifesciences-share_analyst.jpg\";a:2:{s:2:\"id\";i:73223;s:11:\"source_type\";s:13:\"media-library\";}s:94:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/nectar-lifesciences-share_analyst-1024x536.jpg\";a:2:{s:2:\"id\";i:73223;s:11:\"source_type\";s:13:\"media-library\";}s:117:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132523\/nectar-lifesciences-share_analyst.jpg\";a:2:{s:2:\"id\";i:73223;s:11:\"source_type\";s:13:\"media-library\";}s:126:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132523\/nectar-lifesciences-share_analyst-1024x536.jpg\";a:2:{s:2:\"id\";i:73223;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["87"],"rank_math_focus_keyword":["Nectar Lifesciences"],"rank_math_title":["Nectar Lifesciences Q4 Results 2026: Date, Revenue &amp; Analyst Outlook"],"rank_math_description":[" Nectar Lifesciences Q4 results expected May 2026. Revenue estimate Rs 680\u2013730 Cr, PAT Rs 35\u201350 Cr. API exports and US FDA compliance key. Analyst targets up to Rs 85."],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["73219"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["8384"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17132344\/nectar-lifesciences-Q4-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=73214"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73214\/revisions"}],"predecessor-version":[{"id":73224,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73214\/revisions\/73224"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/73219"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=73214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=73214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=73214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}